disseminated renal cancerlow-dose cytokinesefficacy of cytokine combinationsдиссеминированный рак почкималые дозы цитокиновэффективность комбинации цитокинов1.1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. М., 2005.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. М., 2005.2.2. DeVita V. Jr., Hellman S., Rosenberg S. et al. Cancer principles and practice of oncology. 7th ed. Philadelphia, Pa: Lippincott W&W, 2004.DeVita V. Jr., Hellman S., Rosenberg S. et al. Cancer principles and practice of oncology. 7th ed. Philadelphia, Pa: Lippincott W&W, 2004.3.3. Margolin K. Interleukin-2 in the treat- ment of renal cancer. Semin Oncol 2000;27(2):194—203.Margolin K. Interleukin-2 in the treat- ment of renal cancer. Semin Oncol 2000;27(2):194—203.4.4. Atkins M., Regan M., McDermott D. et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10):3601—5.Atkins M., Regan M., McDermott D. et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10):3601—5.5.5. Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recom- binant interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998;338:1272.Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recom- binant interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998;338:1272.6.6. Atzpodien J., Kirchner H., Jonas U. et al. Interleukin-2 and interferon-a2a based immunotharapy in advanced renal cell car- cinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22(7):1188—94.Atzpodien J., Kirchner H., Jonas U. et al. Interleukin-2 and interferon-a2a based immunotharapy in advanced renal cell car- cinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22(7):1188—94.7.7. Calugiuri M.A. Low-dose recombinant interleukin-2 therapy: rationale and poten- tial clinical applications. Am J Clin Oncol 1994;17:199.Calugiuri M.A. Low-dose recombinant interleukin-2 therapy: rationale and poten- tial clinical applications. Am J Clin Oncol 1994;17:199.8.8. Gitlitz B., Figlin R. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003;3(3):589—600.Gitlitz B., Figlin R. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003;3(3):589—600.9.9. Lissoni P., Barni S., Ardizzoia A. et al. A randomized study of low-dose inter- leukin-2 plus interferon-alpha first line therapy for metastatic RCC. Tumor 1993;79:397—400.Lissoni P., Barni S., Ardizzoia A. et al. A randomized study of low-dose inter- leukin-2 plus interferon-alpha first line therapy for metastatic RCC. Tumor 1993;79:397—400.